RxDoctor Payments Data

Thomas Dohlman, MD

Ophthalmology · Boston, MANPI 1174938120

Payments from drug & device makers

What this record shows

This record is dominated by grants: $75,000 of the $87,277 with a category attached, or 85.9%. Alcon Research LLC accounts for 85.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $75,021 and has fallen 87.9% since, to $9,072 in 2025. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$87,277in general payments, 2019–2025

Across 22 payments — averaging $3967.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$75K
  • Glaukos Corporation$10K
  • Biotissue Holdings Inc.$2K
  • Dompe US, Inc.$112
  • Alcon$90
  • W. L. Gore & Associates, Inc.$39

What the payments were for

  • Consulting fees$8,0639%
  • Grants$75,00086%
  • Travel & lodging$2,4163%
  • Food & beverage$1,7982%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,277 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$46,798
Medicare patients
179
Services billed
487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj16$452,288
XiidraLifitegrast13$8,711
Prednisolone Acetate119$4,088
MoxifloxacinMoxifloxacin Hcl149$3,993
ValacyclovirValacyclovir Hcl20$1,273
Doxycycline Monohydrate23$1,050
Gatifloxacin12$808
ErythromycinErythromycin Base62$779
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat20$301
Timolol Maleate21$301
Latanoprost19$260
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim35$241
Brimonidine Tartrate20$199
Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate11$154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$112$452,28816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →